Clinical Trial Detail

NCT ID NCT02619253
Title Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Roberto Pili
Indications

ureter transitional cell carcinoma

urethra transitional cell carcinoma

renal cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

Therapies

Pembrolizumab + Vorinostat

Age Groups: adult

No variant requirements are available.